Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis

References

• National Psoriasis Foundation. About psoriasis: statistics. Available from http://www.psoriasis.org/netcommunity/learn_statistics. Accessed February 28, 2013
   Google Scholar
• Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26:3–11
   PubMed Web of Science ®Google Scholar
• Gladman DD. Psoriatic arthritis from Wright’s era until today. J Rheumatol Suppl. 2009;83:4–8
   PubMedGoogle Scholar
• Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145:700–3
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493–9
   PubMed Web of Science ®Google Scholar
• Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J. 2010;31:1000–6
   PubMed Web of Science ®Google Scholar
• Han C, Lofland JH, Zhao N, et al. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2011;10:843–50
   PubMed Web of Science ®Google Scholar
• Husted JA, Tom BD, Farewell VT, et al. Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2012;64:758–65
   PubMed Web of Science ®Google Scholar
• Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45:151–8
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–4
   PubMed Web of Science ®Google Scholar
• Taylor WJ, Mease PJ, Adebajo A, et al. Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. J Rheumatol. 2010;37:1885–91
   PubMed Web of Science ®Google Scholar
• Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2012;51:275–83
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14–7
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–90
   PubMed Web of Science ®Google Scholar
• Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147--55
   PubMed Web of Science ®Google Scholar
• Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2012;24:169–78
   PubMed Web of Science ®Google Scholar
• Puig L, Strohal R, Fuiman J, et al. High prevalence of the metabolic syndrome in patients with chronic plaque psoriasis: Impact of etanercept therapy on cardiometabolic biomarkers. J Dermatol Treat. 2013;24:169–78
   Google Scholar
• Thaci D, Galimberti R, Amaya-Guerra M, et al. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. J Eur Acad Dermatol Venereol. 2013. Jul 15. doi: 10.1111/jdv.12207. [Epub ahead of print]
   Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2010. Diabetes Care. 2010;33:S11–61
   PubMed Web of Science ®Google Scholar
• Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Framingham Heart Study. Hard coronary heart disease (10-year risk). Available from http://www.framinghamheartstudy.org/risk/hrdcoronary.html. Accessed February 28, 2013
   Google Scholar
• Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–421
   Google Scholar
• Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–9
   PubMed Web of Science ®Google Scholar
• Kind P, Hardman G, Macron S. UK population norms for EQ-5D (Measurement and Valuation of Health National Survey). Available from http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20172.pdf. Accessed February 28, 2013
   Google Scholar
• Sobocki P, Ekman M, Agren H, et al. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health. 2007;10:153–60
   PubMed Web of Science ®Google Scholar
• Lillegraven S, Kvien TK. Measuring disability and quality of life in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:827–40
   PubMed Web of Science ®Google Scholar
• van Stel HF, Buskens E. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual Life Outcomes. 2006;4:20--9
   PubMed Web of Science ®Google Scholar
• Xie J, Wu EQ, Zheng ZJ, et al. Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke. 2006;37:2567–72
   PubMed Web of Science ®Google Scholar
• Ståhl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005;3:56--64
   PubMedGoogle Scholar
• Glasziou P, Alexander J, Beller E, et al. Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes. 2007;5:21--32
   PubMed Web of Science ®Google Scholar
• The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208
   PubMed Web of Science ®Google Scholar
• Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lipincott-Raven, 1996. p. 191–201
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–108
   PubMed Web of Science ®Google Scholar
• Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79--86
   PubMedGoogle Scholar
• Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24:547–61
   PubMed Web of Science ®Google Scholar
• Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528–38
   PubMed Web of Science ®Google Scholar
• Hays RD, Martin SA, Sesti AM, et al. Psychometric properties of the medical outcomes study sleep measure. Sleep Med. 2005;6:41–4
   PubMed Web of Science ®Google Scholar
• Rejas J, Ribera MV, Ruiz M, et al. Psychometric properties of the MOS (medical outcomes study) sleep scale in patients with neuropathic pain. Eur J Pain. 2007;11:329–40
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365
   PubMed Web of Science ®Google Scholar
• Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785–96
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Azfar RS, Mehta NN. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol. 2010;130:919–22
   PubMed Web of Science ®Google Scholar
• Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145:379–82
   PubMed Web of Science ®Google Scholar
• Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20:416–22
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2012;72:211–6
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP. Comorbidities of psoriatic arthritis – metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39:437–40
   PubMedGoogle Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–9
   PubMed Web of Science ®Google Scholar
• Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012;51:552–6
   PubMed Web of Science ®Google Scholar
• Patel RV, Shelling ML, Prodanovich S, et al. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011;26:1036–49
   PubMed Web of Science ®Google Scholar
• Mente A, Yusuf S, Islam S, et al. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol. 2010;55:2390–8
   PubMed Web of Science ®Google Scholar
• Navab M, Reddy ST, Van Lenten BJ, et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222–32
   PubMed Web of Science ®Google Scholar
• Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244–50
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273:197–204
   PubMed Web of Science ®Google Scholar